Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CEO Jason Coloma sold 11,227 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total value of $297,178.69. Following the completion of the sale, the chief executive officer directly owned 38,773 shares in the company, valued at approximately $1,026,321.31. This represents a 22.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Maze Therapeutics Price Performance
Shares of MAZE traded up $0.34 during midday trading on Friday, hitting $26.21. The company’s stock had a trading volume of 273,266 shares, compared to its average volume of 637,671. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a one year low of $14.27 and a one year high of $53.65. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. The company’s fifty day simple moving average is $28.74 and its two-hundred day simple moving average is $31.20.
Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). As a group, equities analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on MAZE
Institutional Trading of Maze Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics in the second quarter valued at approximately $133,502,907. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics during the 2nd quarter worth approximately $122,983,582. BlackRock Inc. bought a new stake in Maze Therapeutics during the 2nd quarter worth approximately $104,525,000. Jupiter Topco LLC acquired a new position in Maze Therapeutics in the 2nd quarter valued at approximately $101,764,000. Finally, Janus Henderson Group PLC increased its position in Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after acquiring an additional 2,390,713 shares during the period.
Maze Therapeutics Company Profile
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Articles
- Five stocks we like better than Maze Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
